chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Back pain, Body temperature, Decreased appetite, Fatigue
Clinical narrative: Neck pain; Tingling all over body; achey/weakness all over; achey/weakness all over; severe headache; Fatigue; Lack of appetite; Fever ~100 degrees Fahrenheit; Upper central back pain; Lingering fatigue randomly throughout the following couple days.; inability to lift either arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Jun2021 at 18:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The medical history included thalassemia (low iron due to small blood cells, similar to anaemia), adult acne, allergy to latex and vinyl. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The concomitant medications included escitalopram (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN), ascorbic acid (VIT C), cyanocobalamin (VIT B12) and zinc (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates and unknown if on going. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13May2021 at 18:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient also took previously morphine (MANUFACTURER UNKNOWN) and hydromorphone hydrochloride (DILAUDID) on unknown dates and experienced allergy. On 03Jun2021 at 20:00, for 24 hours, the patient experienced neck pain, tingling all over body and felt as though body got hit by oncoming traffic, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue randomly throughout the following couple of days. On the same day, the patient underwent body temperature test and the result was approximately 100 degrees fahrenheit. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events neck pain, tingling all over body, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue were resolved with sequelae on an unknown date in Jun2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Movement disorder, Neck pain, Pain, Paraesthesia
Clinical narrative: Neck pain; Tingling all over body; achey/weakness all over; achey/weakness all over; severe headache; Fatigue; Lack of appetite; Fever ~100 degrees Fahrenheit; Upper central back pain; Lingering fatigue randomly throughout the following couple days.; inability to lift either arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Jun2021 at 18:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The medical history included thalassemia (low iron due to small blood cells, similar to anaemia), adult acne, allergy to latex and vinyl. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The concomitant medications included escitalopram (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN), ascorbic acid (VIT C), cyanocobalamin (VIT B12) and zinc (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates and unknown if on going. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13May2021 at 18:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient also took previously morphine (MANUFACTURER UNKNOWN) and hydromorphone hydrochloride (DILAUDID) on unknown dates and experienced allergy. On 03Jun2021 at 20:00, for 24 hours, the patient experienced neck pain, tingling all over body and felt as though body got hit by oncoming traffic, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue randomly throughout the following couple of days. On the same day, the patient underwent body temperature test and the result was approximately 100 degrees fahrenheit. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events neck pain, tingling all over body, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue were resolved with sequelae on an unknown date in Jun2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Neck pain; Tingling all over body; achey/weakness all over; achey/weakness all over; severe headache; Fatigue; Lack of appetite; Fever ~100 degrees Fahrenheit; Upper central back pain; Lingering fatigue randomly throughout the following couple days.; inability to lift either arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Jun2021 at 18:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The medical history included thalassemia (low iron due to small blood cells, similar to anaemia), adult acne, allergy to latex and vinyl. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The concomitant medications included escitalopram (MANUFACTURER UNKNOWN), spironolactone (MANUFACTURER UNKNOWN), ascorbic acid (VIT C), cyanocobalamin (VIT B12) and zinc (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates and unknown if on going. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13May2021 at 18:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient also took previously morphine (MANUFACTURER UNKNOWN) and hydromorphone hydrochloride (DILAUDID) on unknown dates and experienced allergy. On 03Jun2021 at 20:00, for 24 hours, the patient experienced neck pain, tingling all over body and felt as though body got hit by oncoming traffic, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue randomly throughout the following couple of days. On the same day, the patient underwent body temperature test and the result was approximately 100 degrees fahrenheit. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events neck pain, tingling all over body, achy/weakness all over, inability to lift either arm, severe headache, fatigue, lack of appetite, fever approximately 100 degrees fahrenheit, upper central back pain and lingering fatigue were resolved with sequelae on an unknown date in Jun2021.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular, Muscle spasms, Muscle twitching
Clinical narrative: Muscle cramping; Twitching in legs and feet about 15-25 Times a day; period is very irregular (has always been regular); This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20May2021 at 11:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to antibiotic. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22May2021, the patient experienced muscle cramping and twitching in her legs and feet about 15-25 times a day and period was very irregular (had always been regular). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle cramping, twitching in legs and feet about 15-25 times a day and period was very irregular were not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Both vaccines made me start my period early; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 18Mar2021 at 10:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 08Apr2021 at 10:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in 2021, the patient experienced both vaccines made her start her period early. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event both vaccines made her start her period early was resolved on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Dysmenorrhoea, Headache, Heavy menstrual bleeding
Clinical narrative: Started menstrual cycle next day and was not due for 20 days/ It was a heavy flow with cramping; Started menstrual cycle next day and was not due for 20 days/ It was a heavy flow with cramping; Ongoing headaches since the vaccine; Taste of metal as soon as shot was administered; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications in two weeks. On 13Apr2021, the patient experienced taste of metal as soon as shot was administered. On 14Apr2021, the patient's menstrual cycle started next day and was not due for 20 days. It was a heavy flow with cramping. The patient had ongoing headaches since the vaccine, three months now. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events taste of metal as soon as shot was administered and started menstrual cycle next day and was not due for 20 days/ it was a heavy flow with cramping was resolved with sequelae (reported as recovered with lasting effects) on an unknown date in 2021. The clinical outcome of the event ongoing headaches since the vaccine was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 12.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dysmenorrhoea, Menstruation irregular
Clinical narrative: Started period early after second shot.; Having cramps for the first time and they are very painful.; Diarrhea; This is a spontaneous report from a non-contactable consumer, the patient. A 12-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0191) via an unspecified route of administration in the left arm on 14Jun2021 at 07:30 (at the age of 12-years-old) as a single dose for COVID-19 immunisation. Medical history included occasional migraines. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included fluticasone propionate (FLONASE) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 24May2021 at 08:00 (at the age of 12-years-old) as a single dose for COVID-19 immunisation. On 16Jun2021, the patient started period early after second shot. She was having cramps for the first time and they are very painful. The patient also had diarrhea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events started period early after second shot; she was having cramps for the first time and they are very painful and diarrhea was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue, Nausea, Pain
Clinical narrative: Altered taste; Tongue burning; Nausea; Shakes; Chills; Injection site redness; Pain; Weakness; Extreme fatigue; This is a spontaneous report from a contactable nurse, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the left arm on 14Jun2021 at 12:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and multivitamin (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on an unknown date in May2021 at 16:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. The patient previously also received methylparaben (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and experienced drug allergy. On 14Jun2021 at 12:30, the patient experienced altered taste, tongue burning, nausea, shakes, chills, injection site redness, pain, weakness and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events shakes, chills, injection site redness, pain, weakness and extreme fatigue was resolved on an unknown date in Jun2021 whereas events altered taste, tongue burning and nausea was not resolved at the time of this report on 21Jun2021.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Taste disorder, Tongue discomfort, Tremor, Vaccination site erythema
Clinical narrative: Altered taste; Tongue burning; Nausea; Shakes; Chills; Injection site redness; Pain; Weakness; Extreme fatigue; This is a spontaneous report from a contactable nurse, the patient. A 54-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0196) via an unspecified route of administration in the left arm on 14Jun2021 at 12:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and multivitamin (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on an unknown date in May2021 at 16:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. The patient previously also received methylparaben (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and experienced drug allergy. On 14Jun2021 at 12:30, the patient experienced altered taste, tongue burning, nausea, shakes, chills, injection site redness, pain, weakness and extreme fatigue. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events shakes, chills, injection site redness, pain, weakness and extreme fatigue was resolved on an unknown date in Jun2021 whereas events altered taste, tongue burning and nausea was not resolved at the time of this report on 21Jun2021.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Fatigue, Malaise, Myalgia, Pyrexia
Clinical narrative: Diarrhea several times a day; Fever; Exhausted; Sick feeling; Muscles hurting; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14Jun2021 at 12:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included sertraline hydrochloride (ZOLOFT), trazodone (MANUFACTURER UNKNOWN), amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL XR) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL IR); all were for an unknown indication from an unknown date and unknown if ongoing. On 15Jun2021, the patient experienced diarrhea several times a day, fever, exhausted, sick feeling and muscles hurting. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events diarrhea several times a day, fever, exhausted, sick feeling and muscles hurting was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: Delayed period; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on 25May2021 at 13:00 (at the age of 36-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 16Jun2021 at 13:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine sodium (SYNTHROID) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in 2021, the patient experienced delayed period. The event delayed period did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event delayed period was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Influenza like illness, Rash erythematous
Clinical narrative: Pale target outline on injection site; Headache; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Flu-like symptoms; Feeling spacy; One day of just being really tired/fatigue; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Jun2021 at 11:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included early sjogren's, pre-diabetes, early osteopenia, fibromyalgia, irritable bowel syndrome (IBS) and known allergy to other things. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included fish oil (OMEGA 3) and unspecified daily vitamin; both were from unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27May2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient previously received prochlorperazine maleate (COMPAZINE), cefdinir (OMNICEF) and ciprofloxacin (CIPRO) and experienced drug allergy and was sensitive to polysorbate 80 (MANUFACTURER UNKNOWN). On 17Jun2021, the patient felt spacy and was just being really tired for one day. On 18Jun2021, the day after the vaccine, the patient experienced flu-like symptoms for one day. On 19Jun2021, two days after the vaccine, the patient experienced itchy, red, smooth to a raised rash on the chest, neck, upper arms, back, and possibly scalp plus fatigue, headache, and pale target outline on injection site. The target was mostly gone in a day and the rash had lasted for 2 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department, or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event flu-like symptoms was resolved on 19Jun2021. The clinical outcome of the events itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp was resolved on 21Jun2021. The clinical outcome of the event feeling spacy, one day of just being really tired/fatigue, pale target outline on injection site, and headache was resolved on an unknown date in Jun2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Rash papular, Rash pruritic, Vaccination site discolouration
Clinical narrative: Pale target outline on injection site; Headache; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp; Flu-like symptoms; Feeling spacy; One day of just being really tired/fatigue; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Jun2021 at 11:15 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included early sjogren's, pre-diabetes, early osteopenia, fibromyalgia, irritable bowel syndrome (IBS) and known allergy to other things. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included fish oil (OMEGA 3) and unspecified daily vitamin; both were from unknown date for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 27May2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient previously received prochlorperazine maleate (COMPAZINE), cefdinir (OMNICEF) and ciprofloxacin (CIPRO) and experienced drug allergy and was sensitive to polysorbate 80 (MANUFACTURER UNKNOWN). On 17Jun2021, the patient felt spacy and was just being really tired for one day. On 18Jun2021, the day after the vaccine, the patient experienced flu-like symptoms for one day. On 19Jun2021, two days after the vaccine, the patient experienced itchy, red, smooth to a raised rash on the chest, neck, upper arms, back, and possibly scalp plus fatigue, headache, and pale target outline on injection site. The target was mostly gone in a day and the rash had lasted for 2 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department, or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event flu-like symptoms was resolved on 19Jun2021. The clinical outcome of the events itchy, red, smooth to raised rash on chest, neck, upper arms, back, and possibly scalp was resolved on 21Jun2021. The clinical outcome of the event feeling spacy, one day of just being really tired/fatigue, pale target outline on injection site, and headache was resolved on an unknown date in Jun2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Missed periods; This is a spontaneous report from a contactable healthcare professional, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in 2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 10:45 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 21May2021 at 00:00, the patient experienced missed periods. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event missed periods was unknown at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Amenorrhoea
Clinical narrative: My menstration paused for 3 months following vaccination; This is a spontaneous report from a non-contactable nurse, the patient. A 26-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and shellfish allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On an unknown date, the patient's menstruation paused for 3 months following vaccination. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event menstruation paused for 3 months following vaccination was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Menstrual disorder, Menstruation irregular, SARS-CoV-2 test
Clinical narrative: Strange periods for months after, mostly including getting a second period in the middle of the month despite being on birth control; Strange periods for months after, mostly including getting a second period in the middle of the month despite being on birth control; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 02Mar2021 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had known allergies to carrots and celery. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified birth control for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENCE205) via an unspecified route of administration in the left arm on an unknown date in 2021 as a single dose for COVID-19 immunisation. On 01Apr2021, the patient experienced strange periods for months after, mostly included getting a second period in the middle of the month despite being on birth control. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On an unknown date, the patient underwent nasal swab test and the result was negative. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events strange periods for months after, mostly including getting a second period in the middle of the month despite being on birth control was resolved with sequelae on an unknown date in 2021.  No follow-up attempts are possible. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Fatigue, Headache, Malaise, Nasal congestion
Clinical narrative: Injection site pain; Tiredness; Headache; Feeling unwell; A little congestion; Some chest pain; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 18Jun2021 at 15:15 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included hypoglycemia. Concomitant medication included mylan (MANUFACTURER UNKNOWN) (unspecified) from an unknown date for an unknown indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took tetracycline (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 28May2021 at 15:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. On 19Jun2021 at 20:00, the patient had and was still having some chest pain. It felt like she had just finished a really bad coughing spell and it was achy. It was to the point that yawning or sneezing irritated the pain. The patient also had normal side effects on 20Jun2021, the two days after the second dose - injection site pain, tiredness, headache, feeling unwell, and a little congestion. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site pain, tiredness, headache, feeling unwell, a little congestion and some chest pain was not resolved at the time of the report.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Injection site pain; Tiredness; Headache; Feeling unwell; A little congestion; Some chest pain; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 18Jun2021 at 15:15 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included hypoglycemia. Concomitant medication included mylan (MANUFACTURER UNKNOWN) (unspecified) from an unknown date for an unknown indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took tetracycline (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 28May2021 at 15:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. On 19Jun2021 at 20:00, the patient had and was still having some chest pain. It felt like she had just finished a really bad coughing spell and it was achy. It was to the point that yawning or sneezing irritated the pain. The patient also had normal side effects on 20Jun2021, the two days after the second dose - injection site pain, tiredness, headache, feeling unwell, and a little congestion. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site pain, tiredness, headache, feeling unwell, a little congestion and some chest pain was not resolved at the time of the report.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Heavy menstrual bleeding, Lethargy, Menstruation irregular
Clinical narrative: Starting today the pain from the injection site has spread from my shoulder to my elbow.; Starting today the pain from the injection site has spread from my shoulder to my elbow and have pain in my joints; I am also sore; I am also sore, lethargic; I have a fever of 100.3; Vomited today; I am experiencing irregular heavy menstrual bleeding; I am experiencing irregular heavy menstrual bleeding; This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the right arm on 22Jun2021 at 14:15 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit-hyperactivity disorder (ADHD), postural orthostatic tachycardia syndrome (POTS) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included amfetamine aspartate/ amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL), sertraline hydrochloride (ZOLOFT) and cyanocobalamin (B12);all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 23Jun2021 at 12:00, the patient experienced pain from the injection site had spread from shoulder to elbow, sore, lethargic, had pain in joints, fever of 100.3, vomited and experienced irregular heavy menstrual bleeding after she had not had a period in over a year when her intrauterine device (IUD) was implanted. The patient reported that it was not bad enough to seek medical attention, but she wanted to report these side effects for the data. On 23Jun2021, the patient underwent lab test which included body temperature test and the result was found to be 100.3 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain from the injection site had spread from shoulder to elbow, sore, lethargic, had pain in joints, fever of 100.3, vomited and irregular heavy menstrual bleeding was not resolved at the time of this report.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain, Vomiting
Clinical narrative: Starting today the pain from the injection site has spread from my shoulder to my elbow.; Starting today the pain from the injection site has spread from my shoulder to my elbow and have pain in my joints; I am also sore; I am also sore, lethargic; I have a fever of 100.3; Vomited today; I am experiencing irregular heavy menstrual bleeding; I am experiencing irregular heavy menstrual bleeding; This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the right arm on 22Jun2021 at 14:15 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit-hyperactivity disorder (ADHD), postural orthostatic tachycardia syndrome (POTS) and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included amfetamine aspartate/ amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL), sertraline hydrochloride (ZOLOFT) and cyanocobalamin (B12);all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 23Jun2021 at 12:00, the patient experienced pain from the injection site had spread from shoulder to elbow, sore, lethargic, had pain in joints, fever of 100.3, vomited and experienced irregular heavy menstrual bleeding after she had not had a period in over a year when her intrauterine device (IUD) was implanted. The patient reported that it was not bad enough to seek medical attention, but she wanted to report these side effects for the data. On 23Jun2021, the patient underwent lab test which included body temperature test and the result was found to be 100.3 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain from the injection site had spread from shoulder to elbow, sore, lethargic, had pain in joints, fever of 100.3, vomited and irregular heavy menstrual bleeding was not resolved at the time of this report.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: I haven't had my period since I got my second vaccine shot.; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 24Apr2021 at 10:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL XR) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 03Apr2021 at 10:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Apr2021 at 12:00, the patient experienced she hadn't had her period since she got her second vaccine shot. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event hadn't had her period since she got her second vaccine shot was not resolved at the time of this report.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding, Menstruation irregular
Clinical narrative: Menstrual cycle has become much more irregular and heavier; Menstrual cycle has become much more irregular and heavier; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 22Mar2021 at 09:00 (at the age of 24-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN0161) via an unspecified route of administration in the left arm on 10Apr2021 at 09:00 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history included brain cancer and allergy to fresh frozen plasma. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levetiracetam (KEPPRA) and vitamin K (MANUFACTURER UNKNOWN); both for unknown indication from unknown date and unknown if ongoing. The patient previously received levofloxacin (LEVAQUIN) and ciprofloxacin (MANUFACTURER UNKNOWN) and experienced drug allergy. On an unknown date in Apr2021, the patient's menstrual cycle became much more irregular and heavier. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event menstrual cycle has become much more irregular and heavier was not resolved at the time of reporting.  No follow-up attempts are possible. No further information is expected.